BioLife Solutions (NASDAQ:BLFS) vs. Organigram Global (NASDAQ:OGI) Critical Analysis

BioLife Solutions (NASDAQ:BLFS) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioLife Solutions and Organigram Global, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1	0	3	1	2.80
Organigram Global	1	0	2	0	2.33

BioLife Solutions currently has a consensus target price of $32.00, suggesting a potential upside of 45.19%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, equities research analysts clearly believe BioLife Solutions is more favorable than Organigram Global.

Profitability

This table compares BioLife Solutions and Organigram Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.83%	1.66%
Organigram Global	6.03%	-15.41%	-10.49%

Earnings and Valuation

This table compares BioLife Solutions and Organigram Global”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21 million	11.20	-$4.59 million	($0.11)	-200.36
Organigram Global	$185.07 million	1.03	-$17.70 million	$0.14	9.71

BioLife Solutions has higher earnings, but lower revenue than Organigram Global. BioLife Solutions is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioLife Solutions has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Insider and Institutional Ownership

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 0.1% of Organigram Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

BioLife Solutions beats Organigram Global on 11 of the 15 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.